How India Exports Ondansetron to the World

Ondansetron, a 5-HT3 receptor antagonist, is widely utilized in the United States to prevent nausea and vomiting associated with chemotherapy, radiation therapy, and surgery. The FDA's Orange Book lists numerous approved Abbreviated New Drug Applications (ANDAs) for ondansetron, indicating a competitive generic market. Notably, the FDA has issued safety communications regarding ondansetron. In September 2011, the agency highlighted potential risks of abnormal heart rhythms associated with the drug's use. Subsequently, in December 2012, the FDA announced the withdrawal of the 32 mg intravenous dose due to serious cardiac risks. Despite these safety concerns, the United States remains the primary destination for Indian ondansetron exports, accounting for 58.8% of the total export value. This underscores the importance of stringent compliance with FDA regulations for Indian exporters.

In the European Union, ondansetron is subject to marketing authorization by the European Medicines Agency (EMA) or national competent authorities. The EMA has conducted periodic safety update report single assessments (PSUSAs) for ondansetron, with the most recent assessment published in January 2022. (ema.europa.eu) This assessment led to variations in the product information to enhance safety measures. Compliance with EU Good Manufacturing Practice (GMP) requirements is mandatory for manufacturers exporting to the EU and UK markets.

Ondansetron is included in the World Health Organization's Model List of Essential Medicines, reflecting its significance in global healthcare. The drug is also listed in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality and efficacy across different regions.

In India, ondansetron is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines, including ondansetron, to ensure affordability. Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of pharmaceuticals, ensuring compliance with national regulations.

The primary patents for ondansetron have expired, leading to a robust generic market with multiple manufacturers producing the drug. This has resulted in competitive pricing and widespread availability, benefiting both healthcare providers and patients globally.

In October 2024, the FDA issued Import Alert 66-66, targeting active pharmaceutical ingredients (APIs) that appear to be misbranded under section 502(f)(1) due to labeling deficiencies. While this alert does not specifically mention ondansetron, it underscores the necessity for exporters to ensure compliance with labeling requirements to avoid potential import restrictions.

In January 2022, the EMA published the PSUSA for ondansetron, leading to updates in product information to enhance safety measures. (ema.europa.eu) This reflects the ongoing commitment to monitoring and improving the safety profile of ondansetron within the EU.

These developments highlight the dynamic nature of the regulatory environment for ondansetron and the importance of continuous compliance with international standards to maintain market access.

India's pharmaceutical industry, including the production of Ondansetron, heavily relies on imported Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs), with a significant portion sourced from China. This dependency exposes the supply chain to risks associated with geopolitical tensions and trade disruptions. For instance, prior to 2020, India imported approximately 70% of its APIs from China, underscoring the vulnerability of its pharmaceutical sector to external supply shocks.

The COVID-19 pandemic highlighted these vulnerabilities, prompting the Indian government to implement the Production Linked Incentive (PLI) Scheme in 2020. This initiative aims to bolster domestic API and KSM manufacturing capabilities, thereby reducing reliance on imports. While the PLI scheme has led to increased investment in local production facilities, the transition to self-sufficiency is ongoing, and the industry remains susceptible to external supply chain disruptions in the interim. (pharmanow.live)

Our proprietary trade data from 2022 to 2026 indicates that the top five exporters of Ondansetron from India account for 60.9% of the total export value, with AUROBINDO PHARMA LTD alone contributing 25.8%. This high supplier concentration poses a significant risk; any operational or regulatory issues affecting these key exporters could disrupt the global supply of Ondansetron.

The PLI scheme, introduced in 2020, aims to mitigate such risks by incentivizing a broader base of manufacturers to produce APIs and KSMs domestically. While this policy has encouraged diversification, the full impact on reducing supplier concentration is yet to be realized, and the industry continues to monitor the effectiveness of these measures. (pharmanow.live)

Recent geopolitical events have significantly impacted global supply chains. In March 2026, the closure of the Strait of Hormuz due to escalating conflicts led to a substantial decline in maritime transit, affecting approximately 20% of the world's daily oil supply. This disruption has had cascading effects on various industries, including pharmaceuticals, by increasing transportation costs and causing delays.

Additionally, tensions in the Red Sea and the Strait of Hormuz have further complicated shipping routes, leading to increased freight rates and extended delivery times. These disruptions underscore the vulnerability of pharmaceutical supply chains to geopolitical instability, emphasizing the need for robust risk mitigation strategies.

• Diversify Supplier Base: Encourage the development of additional domestic API and KSM manufacturers to reduce reliance on a limited number of suppliers.

• Enhance Inventory Management: Maintain strategic stockpiles of critical APIs and finished products to buffer against supply chain disruptions.

• Strengthen Logistics Infrastructure: Invest in alternative shipping routes and transportation methods to mitigate the impact of geopolitical disruptions on supply chains.

• Monitor Geopolitical Developments: Establish a dedicated team to track and assess geopolitical events that could affect supply chains, enabling proactive risk management.

• Collaborate with Regulatory Bodies: Engage with international regulatory agencies to ensure compliance and to stay informed about potential regulatory changes that could impact supply chains.

RISK_LEVEL: HIGH